PTPN11 and juvenile myelomonocytic leukemia: Nonetheless, the observed anti-proliferative effects in Ptpn11D61G(−/+) mice and JMML patient-derived hematopoietic stem cells support the notion that Shp2 remains a principal therapeutic target.